Detected ·
cAMPfield Therapeutics
$180M—
cAMPfield Therapeutics raised $180M in Series A financing to advance prifemilast, an oral PDE4 inhibitor, for inflammatory bowel disease, with global Phase 2 trials underway in ulcerative colitis and Crohn's disease.
- Website
- campfieldtx.com
- Amount
- $180 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-06-18 16:07:32 UTC
- Signal ID
- 56441685-8d7b-43f8-af04-ffe76519df0c
As the API returns it
{
"id": "56441685-8d7b-43f8-af04-ffe76519df0c",
"created_at": "2026-06-18T16:07:32.245926Z",
"company_name": "cAMPfield Therapeutics",
"company_website_url": "campfieldtx.com",
"company_linkedin_url": "https://www.linkedin.com/company/campfield-therapeutics",
"event_type": "funding",
"funding_amount": 180000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*cAMPfield Therapeutics raised $180M in Series A financing to advance prifemilast, an oral PDE4 inhibitor, for inflammatory bowel disease, with global Phase 2 trials underway in ulcerative colitis and Crohn's disease.*"
}